Epizyme announces FDA filing acceptance of new drug application and priority review for tazemetostat to treat epithelioid sarcoma

Epizyme announced that the US Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for accelerated approval of tazemetostat, its lead investigational agent.